Immunotherapies Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapies stocks.

Immunotherapies Stocks Recent News

Date Stock Title
May 6 SABS SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 3 CGON CG Oncology reports data from Phase 3 bladder cancer study
May 3 CGON CG Oncology's Promising Bladder Cancer Treatment: Balancing Hope And Risk In Late-Stage Trials
May 3 GMAB Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
May 3 CGON Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May 3 CGON Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
May 3 PDSB PDS Biotechnology Announces Details of Virtual KOL Event
May 2 GMAB Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript
May 2 GMAB Genmab A/S 2024 Q1 - Results - Earnings Call Presentation
May 2 GMAB Genmab reports Q1 results
May 2 GMAB Genmab Announces Financial Results for the First Quarter of 2024
May 2 PDSB PDS Biotechnology names Stephan Toutain as COO
May 2 PDSB PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
May 1 GMAB Genmab Q1 2024 Earnings Preview
May 1 GMAB Genmab: A Complicated Tale
May 1 SLS Sellas reports positive Phase 2 data from AML study, files for patent
May 1 SLS SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
May 1 GMAB Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
Apr 30 GMAB Pfizer and Genmab’s Tivdak wins full FDA approval for cervical cancer
Apr 30 GMAB Pfizer, Genmab cervical cancer therapy wins full FDA approval
Immunotherapies

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags